These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

409 related items for PubMed ID: 16179892

  • 1. Antihypertensive drugs and the heart.
    Diamond JA, Phillips RA.
    Minerva Med; 2005 Aug; 96(4):247-60. PubMed ID: 16179892
    [Abstract] [Full Text] [Related]

  • 2. Hypertensive heart disease.
    Diamond JA, Phillips RA.
    Hypertens Res; 2005 Mar; 28(3):191-202. PubMed ID: 16097361
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E, Muiesan ML.
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [Abstract] [Full Text] [Related]

  • 5. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease.
    Gradman AH, Alfayoumi F.
    Prog Cardiovasc Dis; 2006 Jan; 48(5):326-41. PubMed ID: 16627048
    [Abstract] [Full Text] [Related]

  • 6. Treatment of left ventricular hypertrophy in hypertensive patients.
    Tamargo J, Delpón E, Valenzuela C.
    Eur Heart J; 1993 Nov; 14 Suppl J():102-6. PubMed ID: 8281952
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [The primary and secondary prevention of hypertensive cardiopathy].
    Agabiti-Rosei E, Muiesan ML.
    Ital Heart J; 2000 Jun; 1 Suppl 2():59-66. PubMed ID: 10905130
    [Abstract] [Full Text] [Related]

  • 13. Further evidence for low-dose combinations in patients with left ventricular hypertrophy.
    Dahlöf B.
    J Hum Hypertens; 2005 Jun; 19 Suppl 1():S9-14. PubMed ID: 16075032
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Left ventricular hypertrophy: a pressure-independent cardiovascular risk factor.
    Messerli FH, Ketelhut R.
    J Cardiovasc Pharmacol; 1993 Jun; 22 Suppl 1():S7-13. PubMed ID: 7507540
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Antihypertensive treatment and left ventricular hypertrophy].
    Agabiti-Rosei E, Muiesan ML, Rizzoni D.
    Ann Ital Med Int; 1993 Oct; 8 Suppl():97S-103S. PubMed ID: 8117529
    [Abstract] [Full Text] [Related]

  • 19. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB, Dahlöf B.
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [Abstract] [Full Text] [Related]

  • 20. Effect of antihypertensive therapy on left ventricular hypertrophy and on its pathophysiologic sequelae.
    Messerli FH.
    Blood Press Suppl; 1992 Feb; 1():35-6; discussion 37. PubMed ID: 1343271
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.